Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995 over 6 months.
This study examined the effects of the long-acting selective mini somatostatin analogue (SMS) 201-995 in two acromegalic patients who were treated for 3 and 6 months, respectively. During treatment the mean growth hormone levels (25.3 and 20.8 ng/ml vs 5.9 and 10.6 ng/ml) and somatomedin C levels (6.2 and 6.2 IU/ml vs 3.3 and 3.8 IU/ml) decreased and the patients reported an improvement in their symptoms. The main side effect was an increase in stool fat excretion which did exceed the normal range (less than 7 g/day) in one patient. Five acromegalics who received 2 X 50 micrograms SMS 201-995/day for 5 days showed a significant increase of stool fat excretion (1.7 vs 3.5 g/day; p less than 0.05). Fasting blood glucose levels, glucose tolerance, and glycosylated hemoglobin were not essentially effected. It is concluded that SMS 201-995 offers new possibilities in the treatment of acromegaly. The gastrointestinal and diabetogenic side effects of this substance, however, should be carefully monitored.
Plewe
G
G
Schrezenmeir
J
J
Nölken
G
G
Krause
U
U
Beyer
J
J
Kasper
H
H
del Pozo
E
E
D000172:Acromegaly / Q000097:blood / Q000188:drug therapy*; D000239:Adenoma, Acidophil / Q000097:blood / Q000188:drug therapy*; D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005260:Female; D005951:Glucose Tolerance Test; D006442:Glycated Hemoglobin / Q000378:metabolism; D013006:Growth Hormone / Q000097:blood; D006801:Humans; D008134:Long-Term Care; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000097:blood / Q000188:drug therapy; D015282:Octreotide; D010911:Pituitary Neoplasms / Q000097:blood / Q000188:drug therapy*; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000970:Antineoplastic Agents; D006442:Glycated Hemoglobin; D013006:Growth Hormone; D015282:Octreotide; D013004:Somatostatin